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and Florence, Italy
Objective: This study evaluated the 2-year safety and effectiveness of the European First-in-Human INNOVATION trial
for the INCRAFT AAA Stent Graft system (Cordis Corp, Bridgewater, NJ), an ultra-low-proﬁle device for the treatment
of abdominal aortic aneurysms.
Methods: From March 2010 to June 2011, the INNOVATION prospective multicenter trial involving six centers in Europe
enrolled and treated 60 asymptomatic patients (95% male; mean age, 74.4 6 6.9 years) with the INCRAFT System. Main in-
clusioncriteria includedproximalaorticneck lengthof15mmormorewithadiameterupto27mm;distal iliac landingzoneswith
a length greater than 10mmand a diameter between 9 and18mm; and aortic bifurcation >18mm in diameter and access vessels
large enough to accept the 14F outer diameter of the delivery system. The primary end point was technical success at 1 month;
2-year safety end points included the absence of device- or procedure-related major adverse events, absence of type I or III
endoleaks, and maintenance of device integrity through 2 years of follow-up. Study oversight was provided by a Data Safety
MonitoringBoardwitheventadjudicationbyaClinicalEventsCommitteeandimaginganalysisbyan independentcore laboratory.
Results: Of 60 successfully treated patients, two did not come back for their 1-month evaluation but remained enrolled in
the study; 56 were evaluated at 1 year and 52 at 2 years. Of the 58 patients, 56 met the 1-month primary safety and
effectiveness end point (97%; 95% conﬁdence interval, 88%-100%). All patients were free from aneurysm enlargement
through 2 years. There were no type I or III endoleaks at the 2-year time point. All-cause mortality at 2 years was 11.5%,
and no death was device or procedure related. In total, three patients required a postprocedure intervention, two to repair
a type I endoleak and one for limb occlusion. Core laboratory evaluation of the postoperative imaging studies docu-
mented absence of endograft migration and stent fractures in all patients.
Conclusions: The INCRAFT AAA Stent Graft System provides a durable solution for patients with abdominal aortic
aneurysms, with a low frequency of device-related events through 2 years of follow-up. (J Vasc Surg 2015;61:1-8.)Abdominal aortic aneurysms (AAAs) continue to
account for signiﬁcant mortality. More than 10,000 deaths
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AAA in the United States that year, the mortality rate
was 41% when the aneurysm was ruptured, compared
with 1.9% when the aneurysm was intact.1 These and other
data argue for early diagnosis and treatment of AAA, with
either traditional open surgical or less invasive endovascular
techniques. Neither treatment option is without risk, and
whereas endovascular aneurysm repair (EVAR) is associ-
ated with signiﬁcant reductions in early morbidity and mor-
tality, anatomic constraints limit its applicability in a
signiﬁcant proportion of patients. Further, the long-term
durability of EVAR, although improved considerably in
the last decade, remains less than ideal.
The INCRAFT System was designed to address the
applicability and durability of EVAR in the population of
patients with infrarenal AAA, with particular reference to
the need to safely traverse smaller and more diseased iliac
access vessels.2 As an additional design goal, ease of use
was addressed by creating a limited number of device sizes
and lengths that could treat the wide variety of anatomic
variations encountered. Whereas preliminary results with1
Fig 1. INCRAFT AAA Stent Graft System (bifurcation and limbs) with delivery system in different sizes.
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2 Torsello et al January 2015the new INCRAFT System showed promising outcomes,
the theoretical compromise on endograft durability due
to size reduction of the prosthesis and introducer system
at midterm was not yet evaluated.3 Herein we present
the results from this patient group, with complete outcome
data, 2 years after implantation.
METHODS
The INNOVATION study is a multicenter, open-
label, prospective, nonrandomized study of the ﬁrst in-
human use of the INCRAFT System in subjects with
infrarenal AAA. The trial was registered on ClinicalTrials.
gov (NCT01106391) before enrollment of the ﬁrst pa-
tient, and Competent Authority approval was obtained.
The study was conducted in accordance with the Interna-
tional Conference on Harmonization Guidelines, Good
Clinical Practices, Declaration of Helsinki, ISO 14155-1
and 14155-2. Local ethics committee approvals were ob-
tained, and all patients provided written informed consent
before participation.
Patient population. Among 78 screened patients who
were consented, 60 candidates (77%) met the inclusion and
exclusion criteria and underwent device implantation at six
sites in Germany and Italy. On the basis of site-determined
measurements and driven by the INCRAFT System sizes
available during this study, patients considered candidates
for open surgical repair were deemed eligible. The primary
entry criteria included maximum AAA diameter $4.5 cm
in women, $5 cm in men, and >4 cm with an increase
$0.5 cm during the preceding 6 months or $1.5 times
that of the reference aortic diameter. Patients with saccular
aneurysms were eligible for inclusion irrespective of the sac
diameter. Subjects were required to have access vessels of a
size compatible with the 14F outer diameter delivery sys-
tem. Additional anatomic eligibility criteria included a
proximal neck length $15 mm with diameter of 20 to27 mm and iliac landing zones $10 mm in length and 9 to
18 mm in diameter.
Device. The INCRAFT AAA Stent Graft System is a
next-generation bifurcated endovascular graft (Fig 1) that
was re-engineered from a conventional bifurcated stent
graft system.4 The INCRAFT System is characterized by a
trimodular design in a ﬂexible ultra-low-proﬁle delivery
system. (During the INNOVATION study, the INCRAFT
System was available in two aortic bifurcate [outer wall
aortic treatment size 20 to 26.9 mm] and ﬁve limb sizes
[outer wall iliac treatment size 9 to 17.9 mm]. For future
clinical use, the system will come in four aortic bifurcate
sizes [aortic treatment size 17 to 31 mm] and 19 limb
diameters [iliac treatment size 7 to 22 mm]). There are two
variations of the delivery system, one for the aortic bifur-
cate prostheses and one for the iliac limb prostheses. The
delivery system for the aortic bifurcate prosthesis has an
inner diameter of 13F (14F outer diameter) with an inte-
grated and braided sheath introducer. It was designed to
allow partial repositioning of the bifurcate after initial
deployment but before proximal ﬁxation, allowing precise
proximal placement of the prosthesis. Full deployment of
the aortic bifurcate does not require a cap, simplifying the
retrieval of the delivery system at the end of the procedure
(Fig 2). The delivery system for the iliac limb prosthesis is
similar to that of the aortic bifurcate prosthesis but does
not have an integrated sheath introducer and is supplied in
a smaller shaft diameter (12.5F outer diameter). Aneurysm
repair is typically accomplished with three components, the
aortic bifurcate prosthesis main body and two iliac limb
prostheses. Additional iliac limb prostheses can be
deployed when additional distal extension length is desired.
The endograft is constructed of a seamless, low-
porosity, woven polyester graft supported by a series
of short, electropolished, self-expanding laser-cut nitinol
stent-rings throughout the entire length of the graft.
Fig 2. Positioning of the INCRAFT just below the origin of the
left renal artery.
Fig 3. Markers showing the maximum and minimum overlap for
the iliac limbs.
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nitinol tube with minimized crimp proﬁle and are sutured
to the inner surface of the graft material. Radiopaque
markers are afﬁxed to the device to facilitate ﬂuoroscopic
positioning. The graft edge markers of the aortic bifurcate
are positioned immediately above the graft edge to aid in
precise proximal positioning. The aortic bifurcate pros-
thesis has two infrarenal sealing stents and a proximal trans-
renal bare stent with integral laser-cut barbs to prevent
migration of the endograft. The proximal apices of the
transrenal stent are bent slightly inward to reduce friction
along the aortic luminal surface.
The aortic bifurcate varies in trunk diameter sizes, but all
have the same length. The legs of the trunk are designed to
allow intraprocedural length adjustment of up to 3 cm
between the modular components (Fig 3), aiding in the
distal placement precision and potentially reducing the
need for extensions. Suture knots on the outer surface of
the limb prostheses act as an interlocking mechanism with
the endoskeletal stents of the bifurcate to increase the
modular junction force and to allow a minimal overlap length
of 2 cm. Amore detailed description of the graft and available
sizes used in the study is speciﬁed in a previous publication.3
End points. The primary efﬁcacy end point of the
study was technical success, deﬁned by successful devicedeployment at the desired location without a type I, III,
or IV endoleak at the conclusion of the procedure. Major
adverse events were deﬁned as any death, myocardial
infarction, stroke, or occurrence of renal failure. The pri-
mary safety end point was deﬁned by the absence of a
type I, III, or IV endoleak or a device- or procedure-
related major adverse event (death, myocardial infarction,
stroke, or renal failure) at 1 month. Secondary end points
were measured at 1 month, 6 months, 1 year, and 2 years
and included stent fracture, graft thrombosis, migration
(>5 mm), and device explantation. Vital signs and medi-
cations were recorded at discharge through 2 years, and
subsequent follow-up will occur annually through 5 years.
Follow-up imaging included abdominal computed to-
mography (CT) and abdominal plain ﬁlm radiographs for
assessment of the stent graft integrity and fracture. Adverse
events were classiﬁed by relatedness to the device or to the
procedure, severity (mild, moderate, or severe), whether
they were serious, and whether they met the criteria for an
unanticipated serious adverse device effect.
Data analysis. Independent clinical research associates
performed source data veriﬁcation for completeness and ac-
curacy of all source documentation. CT images, plain ﬁlm
abdominal radiographs, and procedure arteriograms were
reviewed by an independent core laboratory (M2S, West
Lebanon, NH), and all protocol-deﬁned major adverse
events and type I, III, and IV endoleaks were adjudicated
by a Clinical Events Committee (CEC) composed of three
independent experts not participating as investigators in
the trial. The Data and Safety Monitoring Board reviewed
the safety data on a periodic basis to determine the ne-
cessity of protocol modiﬁcations or, if major safety issues
arose, to recommend discontinuation of the trial. Data
analysis is based on descriptive statistics rather than formal
hypothesis testing.
RESULTS
Demographics and baseline characteristics. Among
the 60 patients enrolled, 57 (95%) were men with an average
age of 74.5 6 6.9 years (range, 60-94 years) and a mean
aneurysm diameter of 52.6 mm (range, 34.7-101 mm);
Table I. Number of severe anatomic attributes per
patient (based on core laboratory determinations)
No. of severe attributes No. of patients % of patients
At least 5 2 3
At least 4 10 17
At least 3 18 30
At least 2 10 17
At least 1 13 2
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<55 mm were included. The indication for treatment
was saccular morphology or fast growing of the aneurysm
(>5 mm in 6 months). More detailed patient baseline clin-
ical characteristics are summarized in previous publica-
tions.2,3 By the Society for Vascular Surgery grading
classiﬁcation for morphologic risk, more than 50% of the
patients had at least three attributes that met the deﬁnition
of severe hostile anatomy (Table I).5 A detailed distribution
of the anatomy classiﬁcation reveals that more than a third
of the patients presented with challenging morphology at
the aortic bifurcation, iliac seal zone, or access vessels5
(Table II; Fig 4).
Procedural data. The INCRAFT System was success-
fully delivered and deployed in all cases without uninten-
tional branch vessel coverage. The median device
deployment and total procedure time was 36 minutes
and 109 minutes, respectively. A standard trimodular
conﬁguration was used in 56 patients (93%), whereas no
patients required unplanned iliac extensions to reach the
desired distal landing location. Of all 60 patients treated
with the study device, only one patient (1.7%) underwent
predilation of the right iliac artery; no other preoperative
interventions were recorded. In addition, two iliac dilations
and stent placements were performed after placement of
the stent graft. One patient required a proximal cuff.
Endografts were placed with a mean distance between
lowest renal artery and graft edge of 3 mm and an average
iliac coverage of 79% of the length from the common iliac
artery origin to its bifurcation. At the conclusion of the
procedure, 55 patients (92%) had no evidence of type I,
III, or IV endoleaks. The primary efﬁcacy end point of
technical success was achieved in 54 of 60 patients (90%).
Outcome at 30 days. The primary safety end point
was met in 56 of the 58 patients (97%) with core laboratory
imaging available within the 1-month window. No patient
experienced device- or procedure-related major adverse
events, and 56 patients (98.2%) were free from type I, III,
or IV endoleaks at 1 month. Type I endoleaks were noted
in two patients (3.3%). One patient had extensive aortic
and iliac calciﬁcation on preoperative CT imaging studies.
This patient had evidence of a type I endoleak on
completion arteriography. Although the endoleak was
treated by placement of a Palmaz XL stent (Cordis Corp)
into the proximal aortic neck, the endoleak remained
evident on the 1-month CT imaging study. The endoleak
was subsequently treated successfully after reinterventionwith balloon inﬂation at the proximal attachment site on
day 58. A second endoleak, initially reported as type II by
the site, was adjudicated by the CEC as a type I endoleak
on the 1-month CT study. At day 278, this endoleak was
treated and resolved after placement of an aortic extender
cuff and chimney graft to the left renal artery, with place-
ment of endostaples at the proximal attachment site. There
were no protocol-speciﬁed major adverse events, no
device-related serious adverse events, and no unanticipated
adverse device effects through 1 month of follow-up.
Similarly, no patient underwent open surgical conversion,
and there were no limb occlusions, endograft migrations,
secondary procedures, or rehospitalizations through
1 month of follow-up. Among 54 patients with plain
abdominal radiographs evaluated at 1 month by the core
laboratory, no stent fractures or barb separations were
observed.
Outcomes through 2 years. Fifty patients were
eligible for the 2-year visit. There were three patients
who withdrew consent and one who did not return for the
2-year visit; in addition, three patients expired within the
1-year window (1 year 6 6 months) at days 253, 386, and
504 after the procedure because of sepsis, carcinoma, and
multiorgan failure, respectively. Three more patients died
within the 2-year window (2 years 6 6 months) at days
575, 576, and 677 after the procedure; the cause of death
was sepsis, carcinoma, and hemorrhage of unknown cause.
The last patient had no history of endoleaks but was
diagnosed with carcinoma 21 days before his death. The
event was deemed unrelated to the device or the procedure
by the site. As with all serious adverse events, this event was
adjudicated by the CEC and was conﬁrmed to be unrelated
to the device or the procedure. In summary, all deaths were
CEC adjudicated and conﬁrmed to be unrelated to the
device or to the procedure. Absence of type I and III
endoleaks was achieved in all patients with 100% freedom
from aneurysm enlargement, rupture, or conversion to
open surgery at the 1- and 2-year follow-up time points. A
single patient (1.9%) experienced a limb thrombosis. The
event occurred on day 666 after the procedure and was
adjudicated by the CEC as probably related to the proce-
dure and to the device. The thrombosis was thought to be
caused by limb displacement proximally, possibly secondary
to sac contraction and conformational change. No addi-
tional occlusions, endograft migrations, or stent fractures
were noted by core laboratory evaluation through 2-year
follow up (Table III). Other than the two device-related
endoleaks and one iliac limb thrombosis, no additional
serious adverse events were deemed to be device related.
No case of renal artery thrombosis was reported at any
follow-up time point. An overview of all device- and
procedure-related events is presented in Table IV.
Endoleaks. Type I endoleaks were noted in two pa-
tients (3.4%); both were successfully treated with endovas-
cular reinterventions. Further details on these endoleaks
have previously been described.6 No type III or IV endo-
leaks were observed between 1 month and 2 years. At 1-
month follow-up, 55.2% (32 of 58) of the patients were
Table II. Hostile anatomy distribution according to Chaikof et al5 (based on core laboratory determinations)
Hostile anatomy attribute Absent Mild Moderate Severe
Proximal neck ø, mm (<24; 24-26; 26-28; >28) 62% (37/60) 27% (16/60) 8% (5/60) 3% (2/60)
Neck length, mm (>25; 25-15; 15-10; <10) 60% (36/60) 23% (14/60) 8% (5/60) 8% (5/60)
Infrarenal angle, degrees (<20; 20-40; 40-60; >60) 13% (8/60) 57% (34/60) 25% (15/60) 5% (3/60)
Suprarenal angle, degrees (<20; 20-40; 40-60; >60) 85% (51/60) 13% (8/60) 2% (1/60) 0% (0/60)
Aortic thrombus (subjective analysis) 5% (3/60) 73% (44/60) 17% (10/60) 5% (3/60)
Aortic calciﬁcation (subjective analysis) 7% (4/60) 82% (49/60) 12% (7/60) 0% (0/60)
Minimal aortic bifurcation ø, mm (>22; 22-20; 20-18; <18) 38% (23/60) 10% (6/60) 18% (11/60) 33% (20/60)
Left iliac sealing length, mm (>30; 30-20; 20-10; <10) 15% (9/60) 12% (7/60) 33% (20/60) 40% (24/60)
Right iliac sealing length, mm (>30; 30-20; 20-10; <10) 18% (11/60) 20% (12/60) 30% (18/60) 32% (19/60)
Left iliac tortuosity, TI (<1.25; 1.25-1.5; 1.5-1.6; >1.6) 46% (27/59) 46% (27/59) 3% (1/59) 7% (4/59)
Right iliac tortuosity, TI (<1.25; 1.25-1.5; 1.5-1.6; >1.6) 39% (23/59) 51% (30/59) 3% (2/59) 7% (4/59)
Left minimal access ø, mm (>10; 10-8; 8-7; <7) 2% (1/59) 29% (17/59) 24% (14/59) 46% (27/59)
Right minimal access ø, mm (>10; 10-8; 8-7; <7) 2% (1/59) 30% (18/59) 24% (14/59) 44% (26/59)
TI, Tortuosity index.
Because of rounding errors, percentages do not always add up to 100%.
Fig 4. Three-dimensional reconstruction of a computed tomography (CT) angiogram showing severe iliac angulation
in a patient with 10-cm abdominal aortic aneurysm (AAA) before and after implantation of the INCRAFT stent graft.
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endoleaks was probably due to extensive collateral ﬂow in
patients with calciﬁed and narrow-access vessels. The
number of type II endoleaks fell to 38.8% (19 of 49) at
2 years, one of which was newly identiﬁed between 1 and
2 years. Type II endoleaks were adjudicated by the CEC
when there was a discrepancy between the site and the core
laboratory assessment.
Sac size change. Compared with the 1-month CT, no
patient developed aneurysm enlargement through 2 years
of follow-up. An average decrease of 11.4% (6.0 mm) was
observed with $5 mm sac regression in 22 of 49 patients
(45%) at 2 years (Figs 5 and 6). Although not statistically
powered, aneurysm regression seemed to be consistent
regardless of the aneurysm size.
DISCUSSION
Endovascular repair of aortic aneurysms offers signiﬁ-
cant advantages over traditional open surgical techniques,
yet its applicability has been limited to those patientswith aortoiliac anatomy appropriate for currently available
endografts and delivery systems. The report of Schanzer
et al7 documented that approximately 60% of treated pa-
tients had anatomy that fell outside of the prescribed
conservatively interpreted criteria for a particular device’s
instructions for use (IFU). Even with more liberal inter-
pretation of the IFU, approximately one third of patients
still had anatomic conﬁgurations inconsistent with device
recommendations. Among anatomic characteristics most
discrepant from the IFU were proximal aortic neck length
#15 mm in more than 40% of the patients and one or
more external iliac arteries <6 mm in diameter in approx-
imately 30%. Especially calciﬁed, tortuous, and narrow-
access vessels increase the risk for technical failures and
need for secondary procedures.8,9 Besides these, gender
has also been shown to be a contributory risk factor for
treating patients with challenging iliac vessels.10 There-
fore, an increasing number of low-proﬁle devices have
been introduced in clinical practice.11,12 Some of these
devices have been implanted in off-label conditions.
Table III. Effectiveness and safety results through 2 years
Secondary end points 1 Year 2 Years
Device-related end points
Aneurysm enlargement 0.0% (0/53) [0.0%-6.7%] 0.0% (0/50) [0.0%-7.1%]
Stent graft migration 0.0% (0/53) [0.0%-6.7%] 0.0% (0/50) [0.0%-7.1%]
Any endoleak (non-type II) 0.0% (0/53) [0.0%-6.7%] 0.0% (0/50) [0.0%-7.1%]
Type I endoleak 0.0% (0/53) [0.0%-6.7%] 0.0% (0/50) [0.0%-7.1%]
Type III endoleak 0.0% (0/53) [0.0%-6.7%] 0.0% (0/50) [0.0%-7.1%]
Undetermined endoleak 0.0% (0/53) [0.0%-6.7%] 0.0% (0/50) [0.0%-7.1%]
Stent graft fractures 0.0% (0/52) [0.0%-6.8%] 0.0% (0/46) [0.0%-7.7%]
Iliac limb patency 100.0% (53/53) [93.3%-100.0%] 100.0% (45/45) [92.1%-100.0%]
Clinical/safety end points
Major adverse events 1.8% (1/56) [0.0%-9.6%] 11.5% (6/52) [4.4%-23.4%]
Death 1.8% (1/56) [0.0%-9.6%] 11.5% (6/52) [4.4%-23.4%]
Stroke 0.0% (0/56) [0.0%-6.4%] 0.0% (0/52) [0.0%-6.8%]
Q wave myocardial infarction 0.0% (0/56) [0.0%-6.4%] 0.0% (0/52) [0.0%-6.8%]
Renal failure 0.0% (0/56) [0.0%-6.4%] 0.0% (0/52) [0.0%-6.8%]
Thrombosis 0.0% (0/56) [0.0%-6.4%] 1.9% (1/52) [0.0%-10.3%]
Stent graft explantation 0.0% (0/55) [0.0%-6.5%] 0.0% (0/52) [0.0%-6.8%]
The numbers in brackets are 95% conﬁdence intervals.
Table IV. Device- and procedure-related adverse events (AEs) through 2 years
AE category AE description No. of subjects
All serious AEs d 14.8% (8/54) [6.6%-27.1%]
Access site complication Hematoma/bleeding 3.7% (2/54) [0.5%-12.7%]
Target lesion Prosthesis leaks (endoleak I) 3.7% (2/54) [0.5%-12.7%]
Prosthesis occlusion/stenosis 3.7% (2/54) [0.5%-12.7%]
Vessel-speciﬁc complications Dissection 1.9% (1/54) [0.0%-9.9%]
Various Claudication 1.9% (1/54) [0.0%-9.9%]
Othera 5.6% (3/54) [1.2%-15.4%]
The numbers in brackets are 95% conﬁdence intervals.
aSeroma of the groin; elevated creatinine concentration; lymphocele.
Fig 5. Mean abdominal aortic aneurysm (AAA) diameters at 1, 6,
12, and 24 months after implantation.
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I endoleaks.13
The INCRAFT System was designed to address some of
the limitations of currently marketed endografts. The
endograft is constrained within a delivery system with an
outer diameter of 14F (4.7 mm). By the combination of
the braided shaft of the integrated sheath introducer with
the proprietary stent design and crimping proﬁle allowinga high compacting factor during the loading process, the
ultra-low-proﬁle of the delivery systemwas achievedwithout
the need for sacriﬁces in durability. To conﬁrm durability of
the INCRAFT System, however, in vitro fatigue testing was
performed under aggressive conditions to accelerate device
failures and to compare the stent graft design with commer-
cially released devices. In addition, the System completed
400 million cycles of fatigue testing at conditions represen-
tative of actual clinical and physiologic conditions.
Another complexity of endovascular repair is the inaccu-
racy inherent in predicting the ultimate aortoiliac lengths
and diameters from even the most sophisticated preproce-
dure imaging studies.14 The stiffness of guidewires, delivery
systems, and the endografts themselves can markedly alter
the anatomic conﬁguration of the aorta and iliac arteries,
and the postdeployment curvilinear path that an endograft
ultimately takes can be difﬁcult to estimate from preopera-
tive or even intraoperative predeployment imaging studies.
The INCRAFT System was designed to address this limita-
tion with in situ customization features that provide a clini-
cian with a great deal of latitude in deploying the iliac limbs
into the bifurcate device, with the capability to adjust length
up to 3 cm intraprocedurally. This feature has the potential
to minimize the need for iliac extensions, and only 7% of the
patients received an iliac extension in the current study.
Fig 6. Three-dimensional reconstruction of a computed tomography (CT) angiogram showing the aneurysm
shrinkage within 2 years of implantation of the INCRAFT stent graft.
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cult to estimate from preprocedure imaging studies. The
INCRAFT AAA Stent Graft System was designed to allow
accommodation of a broad spectrum of aortoiliac diameters
with a limited number of endograft diameter sizes. Once it is
commercially available, the INCRAFTAAA Stent Graft Sys-
temwill come in 23 codes, four aortic bifurcate sizes, and 19
limb diameters, allowing the treatment of patients with
aortic neck diameters of 17 to 31 mm and iliac diameters
of 7 to 22 mm.
Through 2 years of follow-up, the INCRAFT AAA
Stent Graft System provides a durable solution for patients
with AAAs. Patients with demanding anatomy could also
be successfully treated with a low frequency of device-
related events. The midterm results of the INNOVATION
trial suggest that the INCRAFT System holds great poten-
tial as a novel endograft that expands the population of pa-
tients amenable to EVAR. The 23% proportion of patients
with at least one access vessel <6 mm in diameter exceeds
that of the most available stent grafts.
Treating patients with narrow iliacs has often been
associated with an impact on limb patency.15 However,
during the INNOVATION follow-up, only one limb
thrombosis occurred, which required adjunct procedures
to maintain limb patency. The thrombosis was most prob-
ably caused by limb movement, possibly secondary to sac
remodeling. Importantly, the engineering of the device
allowed its design goals to be achieved without compro-
mising device durability, at least during midterm follow-
up. No stent fractures or type III endoleaks were observed
through the 2-year follow-up time point. Also, the radial
force of the proximal stents in conjunction with the supra-
renal barbs was adequate to prevent migration in all pa-
tients. The clinical manifestations of device performance
include the acceptable 2-year rate of aneurysm sac regres-
sion and the relative rarity of secondary procedures neces-
sary during midterm follow-up.This ﬁrst in-human study has a sample size limited to
60 patients with a current follow-up to 24 months. There-
fore, longer term follow-up and larger studies are needed
to ensure sustained durability results.
CONCLUSIONS
Data from the INNOVATION trial conﬁrm excellent
clinical outcome through 2 years after implantation.
Despite design attributes that allow reduction of the size
of the delivery system to a 13F inner diameter, 14F outer
diameter, device durability is maintained through midterm
follow-up. These observations suggest that the INCRAFT
AAA Stent Graft System is a device with increased applica-
bility over the broad spectrum of aortoiliac anatomic con-
ﬁgurations encountered in patients undergoing EVAR.
Persistence of the low rate of secondary procedures and
aneurysm-related morbidity through long-term follow-up
will provide a minimally invasive solution that compares
favorably with traditional open surgical aneurysm repair.
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